FDA Brief

Warning letters Drugs

FDA warning letter to

ECI Pharmaceuticals, LLC

LowIssued Feb 3, 2022Posted Feb 15, 2022Center for Drug Evaluation and Research | CDER

FDA warned ECI Pharmaceuticals for listing the wrong active ingredient for its estrogen and testosterone drugs, which got them removed from the NDC Directory.

What happened

FDA reviewed the drug listing information ECI Pharmaceuticals submitted through its electronic Drug Registration and Listing System (eDRLS) for two esterified estrogens and methyltestosterone products. FDA found the listing file named conjugated estrogens as an active ingredient, while the labeling sent with the listing named esterified estrogens, and said these are different and not equivalent ingredients. FDA had already sent the firm a deficiency letter on October 26, 2021 and a removal notification on December 10, 2021, after which the products were taken out of FDA's Online NDC Directory.

What FDA found

  1. The listing file named conjugated estrogens as an active ingredient, but the labeling sent with it named esterified estrogens, so the listing did not give the correct name of each active ingredient.

    FD&C Act section 510(j)(1)(C), 21 U.S.C. 360(j)(1)(C); 21 CFR 207
  2. Failing to list the drugs properly is a prohibited act under the FD&C Act.

    FD&C Act section 301(p), 21 U.S.C. 331(p)
  3. Because the drugs were not properly listed with FDA, they are misbranded.

    FD&C Act section 502(o), 21 U.S.C. 352(o); section 301(a), 21 U.S.C. 331(a)

What FDA wants

FDA asks the firm to write within 15 working days describing the specific steps taken to fix the violations, how it will prevent them from happening again, and copies of related documents. If the fixes cannot be finished in that time, the firm must explain the delay and say when they will be done.

Who should pay attention

  • drug companies that submit their own NDC listing files to FDA
  • regulatory affairs staff who keep eDRLS listing data in step with approved labeling
  • pharmacies and prescribers who rely on NDC Directory entries

This is a summary. Read the original letter on fda.gov.

ECI Pharmaceuticals, LLC's FDA history

  1. ECI Pharmaceuticals, LLC

    ECI Pharmaceuticals listed conjugated estrogens instead of esterified estrogens for two drugs, FDA says.

    Low

Full company page

Similar letters to other companies

  1. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  2. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk
  3. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk
  4. Suretec Innovations, LLC

    Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.

    High risk